Special Issue

Strategies of Viral Vectors for Vaccine Development

Message from the Guest Editor

Viral vectors have long been explored as potential tools in medicine. As these vectors grow more and more sophisticated, their applications have expanded. Viral vectors can be used to carry drugs, express heterologous proteins, and even target cancer cells. The scope of this Special Issue will include the development of animal, plant and bacterial virus vectors as a means to produce safe, efficacious and inexpensive vaccines. I/We look forward to receiving your contributions.

Guest Editor

Dr. Kathleen Hefferon

Department of Cell & Systems Biology, University of Toronto, Toronto, ON M5S 1A1, Canada

Deadline for manuscript submissions

31 August 2025



an Open Access Journal by MDPI

Impact Factor 5.2 CiteScore 8.9 Indexed in PubMed



mdpi.com/si/188100

Vaccines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/ vaccines





an Open Access Journal by MDPI

Impact Factor 5.2 CiteScore 8.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2024).

